3 years ago
GSK-Vir treatment sotrovimab reduces COVID-19 hospitalization and death
GlaxoSmithKline Plc and Vir Biotechnology confirmed on Monday that their monoclonal antibody treatment, sotrovimab, reduced hospitalization and death among high-risk COVID-19 patients by 79%. Sotromivab, which...